Raymond James Maintains Strong Buy on Viking Therapeutics, Raises Price Target to $118
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse maintains a Strong Buy rating on Viking Therapeutics (NASDAQ:VKTX) and raises the price target from $116 to $118.
July 25, 2024 | 5:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James analyst Steven Seedhouse maintains a Strong Buy rating on Viking Therapeutics and raises the price target from $116 to $118.
The Strong Buy rating and increased price target from a reputable analyst at Raymond James is likely to positively impact investor sentiment and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100